Aeromics, LLC

New Haven, US · 1 known investors

Aeromics is a clinical-stage biopharmaceutical company developing AER-271, an aquaporin-4 inhibitor to prevent cerebral edema (brain swelling) in severe acute ischemic stroke patients. The therapy targets molecular water channels to improve survival and recovery outcomes while reducing the need for invasive surgical interventions.

BiotechMedical Devices